• Hang-Huang Jin, Tian-Ming Mao, Zhi-Qiang Bai, Yuan Chen, Hai-Long Ji, and Yong Jin.
• Department of Neurosurgery, Zhejiang Taizhou Municipal Hospital, 381 Zhongshan East Road, Jiaojiang District, Taizhou 318000, Zhejiang Province, China.
• Clin. Chim. Acta. 2018 Sep 1; 484: 258-264.

BackgroundCyclophilin A is involved in many inflammatory diseases and its expression is up-regulated after brain injury. We determined if serum cyclophilin A could be used as a marker for severity and 90-day outcome in patients with traumatic brain injury (TBI).MethodsSerum cyclophilin A concentrations were quantified in 105 severe TBI patients and 105 healthy individuals. Its association with Glasgow Coma Scale (GCS) score, 90-day mortality and 90-day poor outcome (Glasgow Outcome Scale score of 1-3) were investigated.ResultsSerum cyclophilin A concentrations were significantly higher in TBI patients than in healthy individuals. Cyclophilin A concentrations had a close relation to GCS scores and showed a high discriminatory ability for 90-day mortality and poor outcome according to area under receiver operating characteristic curve (AUC). Its AUC was in the range of GCS scores. Moreover, its combination with GCS scores significantly improved the predictive performance of GCS scores alone. In addition, serum cyclophilin A emerged as an independent predictor for 90-day mortality, overall survival and poor outcome.ConclusionsIncreased serum cyclophilin A concentrations could reflect trauma severity and unfavorable outcome after head trauma, substantializing cyclophilin A as a potential biomarker for prognostic prediction of TBI.Copyright © 2018 Elsevier B.V. All rights reserved.

17 keywords...

hide…